论文信息 - Authors’ reply to de Oliveira and Iverson

Authors’ reply to de Oliveira and Iverson

We found that glucagon-like peptide-1 receptor (GLP-1R) agonists suppress appetite and lead to clinically beneficial weight loss, improved glycaemic control (in patients with type 2 diabetes), and reduced blood pressure and cholesterol values over 20 weeks1—clinically relevant treatment results.2 The effect is sustained for up to two years in most patients.3 Several large cardiovascular outcome trials, each of up …

M. Christensen | T. Vilsbøll | F. Knop | L. Gluud | A. Junker

[1] Kristen A Iverson. GLP-1R agonists are not a quick fix for weight loss , 2012, BMJ : British Medical Journal.

[2] J. F. D. Oliveira. Utility of GLP-1R agonists in diabetes requires long term study , 2012 .

[3] M. Christensen,et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[4] P. Matthews,et al. The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans , 2011, Cell metabolism.

[5] A. Astrup,et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.

[6] K. Khunti,et al. Impact of weight gain on outcomes in type 2 diabetes , 2011, Current medical research and opinion.

[7] K. Almholt,et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. , 2010, Endocrinology.

[8] R. Patterson,et al. Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes , 2009, Diabetes Care.

[9] J. Holst. The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.